ClinicalTrials.gg
CompletedNCT00722553Updated Dec 17, 2019Results posted

Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

A Phase 2 interventional study of Pralatrexate Injection and Vitamin B12 in Carcinoma, Transitional Cell, Bladder Cancer and Bladder Neoplasm, sponsored by Acrotech Biopharma Inc.. Completed at 19 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-12-17.

Sponsored by Acrotech Biopharma Inc. (part of Aurobindo Pharma) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Carcinoma, Transitional Cell with a site in France — 15 open to participants now, 27 under way, 6 of them phase 3. Carcinoma, Transitional Cell · France.

Enrollment
56th of 61
30 · median 180
Started
2008
with 1 other
Phase 2
22 of 70
3 open now
Registered
5th of 70
by date

Among the 70 studies in Carcinoma, Transitional Cell with a site in France, this one is the 56th largest by enrollment of the 61 interventional ones that give a count, is one of 2 that started in 2008, is one of 22 in phase 2, and was the 5th registered.

Carcinoma, Transitional Cell

632 studies on the registry are indexed under Carcinoma, Transitional Cell; 180 are open to participants now.

Browse Carcinoma, Transitional Cell studies →

Open to participants now

15 of the 70 studies in Carcinoma, Transitional Cell with a site in France are open now. Recruiting first, the newest first:

10 more — sign in →

All 15 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 147 Carcinoma, Transitional Cell studies recruiting now, 121 (82%) set no upper age limit and 11 (7%) stop at 75 or younger; 4 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Carcinoma, Transitional Cell with a site in France, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether pralatrexate, given with vitamin B12 and folic acid, is effective in the treatment of advanced or metastatic bladder cancer. The study will also investigate the safety of pralatrexate with vitamin B12 and folic acid in this patient population. Additionally, this study includes the collection of blood samples to investigate the pharmacokinetics (PK) of pralatrexate in this patient population (PK is the activity of a drug in the body over a period of time, including how the drug is absorbed, distributed in the body, localized in the tissues, and excreted from the body).

03

Conditions studied

  • Carcinoma, Transitional Cell
  • Bladder Cancer
  • Bladder Neoplasm

Keywords

  • Transitional Cell Carcinoma of the Urinary Bladder
  • Transitional Cell Carcinoma
  • Bladder Cancer
  • Urinary Bladder Cancer
  • Bladder
  • Carcinoma
  • Urinary
  • Metastatic
  • Relapsed
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed transitional cell carcinoma of the urinary bladder. Fine needle aspirate will not be accepted.
  • or progressed after treatment with a platinum- and/or methotrexate-based systemic chemotherapy regimen. No more than 1 prior regimen is permitted for recurrent/ disease. Patients has had a chemotherapy-free interval of ≥ 12 months from last dose if most recent prior chemotherapy was in /adjuvant setting and has had ≥ 6-month chemotherapy-free interval in recurrent/metastatic setting. Patient has recovered from the toxic effects of prior therapy. Previous intravesical therapy is allowed. Prior surgical resection is allowed, as long as the patient has recovered.
  • outside a previously irradiated region, per (RECIST).
  • (ECOG) performance status of 0 or 1.
  • At least 18 years of age.
  • Adequate blood, liver, and kidney function as defined by laboratory results.
  • Patient has received 1.0-1.25 mg of oral folic acid daily for at least 7 days of enrollment \& 1 mg intramuscular vitamin B12 within 10 weeks of enrollment.
  • Women of have a negative serum pregnancy test within 14 days prior to enrollment and agree to use medically acceptable and effective from enrollment until at least 30 days after the last dose of pralatrexate.
  • Men who are not surgically sterile and whose partner is of childbearing potential must use medically safe and effective birth control start of pralatrexate until at least 90 days after the last dose of pralatrexate.
  • Accessible for repeat dosing and follow up.
  • Give written .

Exclusion criteria

Exclusion Criteria:

  • Active concurrent primary or prior malignancies occurring within 5 years (except non-melanoma skin cancer, in situ carcinoma of the cervix, or occult, indolent carcinoma of the prostate). If there is a history of prior malignancies other than those exceptions listed above, the patient must be disease free for ≥ 5 years. Patients with other prior malignancies \< 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease. In the case of a single extrapelvic site, irrespective of the patient having a history of previous malignancy, a proof of the metastatic diseased organ will be necessary.
  • More than 1 previous regimen for recurrent/metastatic disease.
  • Evidence of active third-space phenomenon
  • Use of drugs, biologics, or devices within 28 days prior to study enrollment.
  • Previous exposure to other antifolates, including pralatrexate. Previous methotrexate is allowed, only if it was part of an M-VAC or MCV regimen.
  • Women who are pregnant or breastfeeding.
  • Congestive Heart Failure Class III/IV according to (NYHA) Functional Classification.
  • Uncontrolled hypertension.
  • (HIV)-positive diagnosis with a of \< 100 mm3 or detectable viral load within the past 3 months, and receiving combination anti-retroviral therapy.
  • Central nervous system metastatic disease.
  • Major surgery within 2 weeks of study enrollment.
  • Radiation therapy (RT) within 4 weeks (within 3 months for RT to the pelvis) prior to study enrollment.
  • Active infection or any serious underlying medical condition, which would impair the ability of the patient to receive protocol treatment.
  • Dementia or significantly altered mental status that would prohibit the understanding and giving of or limit study compliance.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Dietary Supplement Vitamin B12 & Folic Acid (Vitamin B9)

    Vitamin B12 : 1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate. Folic Acid: 1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.

    Drug: Pralatrexate Injection · Dietary Supplement: Vitamin B12 · Dietary Supplement: Folic Acid

Interventions

  • Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride). Initial dose: 190 mg/m2 Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity. Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met.

    Also known as: FOLOTYN, PDX, Pralatrexate, (RS)-10-propargyl-10-deazaaminopterin

  • Dietary supplementVitamin B12

    1 mg intramuscular injection Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate.

    Also known as: Cyanocobalamin

  • Dietary supplementFolic Acid

    1-1.25 mg orally Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate.

    Also known as: Vitamin B9, Folate, Folacin

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR)

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment.

Secondary outcomes

  1. Duration of Response (DOR)

    Duration of time from when tumor measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent disease or progressive disease (PD) or death was objectively documented. Progression is defined, using RECIST, as an increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. Calculated for those patients with a best overall confirmed or unconfirmed response of CR or PR.

    Time frame: Measured from the first day of documented response for up to 2 years after enrollment.

  2. Clinical Benefit Rate (CBR)

    The number of patients with a best confirmed or unconfirmed response of CR, PR, or stable disease (SD) for at least 24 weeks (approximately 5.5 months)

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks) or per standard of care, but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.

  3. Progression Free Survival (PFS)

    Length of time from study day 1 to the date of radiological evidence of PD (date of computed tomography \[CT\] or magnetic resonance imaging \[MRI\] scan, whichever indicates PD) or death, regardless of cause.

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.

  4. Overall Survival (OS)

    The number of days from study day 1 to death. Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last contact.

    Time frame: Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care if treatment has ended (at least every 12 weeks) for up to 2 years after enrollment. After PD or start of subsequent treatment, OS will be assessed every 4 months.

07

Results

Posted Jul 17, 2012

Participant flow

Patients were enrolled between July 2008 and November 2010 across 10 study sites and 5 countries.

Participant flow — Overall Study
MilestoneFull Population
Started30
Completed30
Not completed0

Outcome measures

PrimaryObjective Response Rate (ORR)

The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR)

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment.
Reported as:
Number · participants
Objective Response Rate (ORR)
participantsEvaluable Population
Objective Response Rate (ORR)1 (— to 17.2)
SecondaryDuration of Response (DOR)

Duration of time from when tumor measurement criteria were met for CR or PR (whichever status was recorded first) until the first date that recurrent disease or progressive disease (PD) or death was objectively documented. Progression is defined, using RECIST, as an increase in the smallest dimension of any target or non-target lesion, or the appearance of new lesions, since baseline. Calculated for those patients with a best overall confirmed or unconfirmed response of CR or PR.

Time frame:
Measured from the first day of documented response for up to 2 years after enrollment.
Reported as:
Median · Days
Duration of Response (DOR)
DaysEvaluable Patients
Duration of Response (DOR)82 (58 to 120)
SecondaryClinical Benefit Rate (CBR)

The number of patients with a best confirmed or unconfirmed response of CR, PR, or stable disease (SD) for at least 24 weeks (approximately 5.5 months)

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks) or per standard of care, but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.
Reported as:
Number · participants
Clinical Benefit Rate (CBR)
participantsEvaluable Population
Clinical Benefit Rate (CBR)3
SecondaryProgression Free Survival (PFS)

Length of time from study day 1 to the date of radiological evidence of PD (date of computed tomography \[CT\] or magnetic resonance imaging \[MRI\] scan, whichever indicates PD) or death, regardless of cause.

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended, for up to 2 years after enrollment.
Reported as:
Median · Months
Progression Free Survival (PFS)
MonthsEvaluable Population
Progression Free Survival (PFS)4.0 (2.1 to 4.5)
SecondaryOverall Survival (OS)

The number of days from study day 1 to death. Patients who had not died (no record of death) or were lost to follow-up were censored at the date of last contact.

Time frame:
Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care if treatment has ended (at least every 12 weeks) for up to 2 years after enrollment. After PD or start of subsequent treatment, OS will be assessed every 4 months.
Reported as:
Median · Months
Overall Survival (OS)
MonthsEvaluable Population
Overall Survival (OS)9.3 (5.6 to 13.2)

Adverse events

Collected over Assessed every 2 weeks while on treatment through safety follow-up visit (35 +/-5 days post-last dose) or early termination visit (at time of withdrawal).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Full Population—17/30 (56.7%)30/30 (100%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventFull Population
stomatitisGastrointestinal disorders6/30
astheniaGeneral disorders2/30
general physical health deteriorationGeneral disorders2/30
pyrexiaGeneral disorders2/30
anaemiaBlood and lymphatic system disorders2/30
neutropeniaBlood and lymphatic system disorders2/30
anorexiaMetabolism and nutrition disorders2/30
toxic skin eruptionSkin and subcutaneous tissue disorders2/30
arthralgiaMusculoskeletal and connective tissue disorders2/30
ascitesGastrointestinal disorders1/30
Most frequent other events
Showing 10 of 51
Most frequent other events
EventFull Population
stomatitisGastrointestinal disorders23/30
astheniaGeneral disorders15/30
anaemiaBlood and lymphatic system disorders11/30
anorexiaMetabolism and nutrition disorders10/30
constipationGastrointestinal disorders10/30
vomitingGastrointestinal disorders10/30
pyrexiaGeneral disorders9/30
nauseaGastrointestinal disorders8/30
neutropeniaBlood and lymphatic system disorders7/30
abdominal painGastrointestinal disorders6/30

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Full Population
<=18 years0
Between 18 and 65 years14
>=65 years16
Age, Continuous
Age, Continuous(years)Full Population
Mean65.8 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Full Population
Female3
Male27
Region of Enrollment
Region of Enrollment(participants)Full Population
France14
United States4
Argentina1
Spain10
Belgium1
08

Study locations

19 sites
  • The University of Arizona Health Sciences Center
    Tucson, Arizona 85724, United States
  • Peachtree Hematology/Oncology Consultants
    Atlanta, Georgia 30318, United States
  • University of Rochester Cancer Center
    Rochester, New York 14642, United States
  • University of Utah, Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • Centro de Terapia Radiante Cumbres (CAICI)
    Rosario, Santa Fe Province 2000, Argentina
  • IONC (Instituto Oncológuci de Cordoba)
    Córdoba, X5004BAL, Argentina
  • Algemeen Ziekenhuis Middelheim
    Antwerp, 2020, Belgium
  • Institut Jules Bordet
    Brussels, 1000, Belgium
  • CH Split Clinic of Oncology and Radiotherapy
    Split, 21000, Croatia
  • CHU Zagreb University Hospital Center Rebro in Zagreb
    Zagreb, 10000, Croatia
  • Clinic of Oncology and Nuclear Medicine, CH "Sestre Milosrdnice"
    Zagreb, 10000, Croatia
  • Institut Sainte Catherine
    Avignon, 84082, France
  • Centre Oscar Lambret
    Lille, 59020, France
  • Centre Hospitalier Rene Dubos
    Pontoise, 95301, France
  • Hopital Foch
    Suresnes, France
  • Institut Gustave Roussy
    Villejuif, 94 805, France
  • Ciutat Sanitari de Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Del Mar - Barcelona
    Barcelona, 8003, Spain
  • Hospital Virgen del Rocio
    Seville, 41013, Spain
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2008, a primary completion of Apr 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2008
First posted
Jul 25, 2008
Start
Jul 2008
Primary completionActual
Apr 2011
CompletionActual
Sep 2011
Results first posted
Jul 17, 2012
Last update
Dec 17, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00722553
Responsible party
Sponsor
First posted
Jul 25, 2008
Start date
Jul 2008
Primary completion
Apr 2011
Completion
Sep 2011
Results posted
Jul 17, 2012
Last update
Dec 17, 2019

Study contacts

Garry Weems, Pharm.D.
study director · Spectrum Pharmaceuticals, Inc
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pralatrexate

Start the discussion